# China Porcine Vaccines Market > China Porcine Vaccines Market Research Report By Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), By Disease Indication (PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD), Others) and By End-user (Veterinary Hospitals, Hog Production Farm) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.14% - **2024:** $ 144 Million - **2025:** $ 151.4 Million - **2035:** $ 250 Million - **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) **Report ID:** MRFR/Pharma/48725-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-porcine-vaccines-market-50482 --- ## Market Summary ## **China Porcine Vaccines Market Overview** As per MRFR analysis, the China Porcine Vaccines Market Size was estimated at 134.25 (USD Million) in 2023. The China Porcine Vaccines Market Industry is expected to grow from 160(USD Million) in 2024 to 375 (USD Million) by 2035. The China Porcine Vaccines Market CAGR (growth rate) is expected to be around 8.051% during the forecast period (2025 - 2035) **Key China Porcine Vaccines Market Trends Highlighted** The growing concern over animal health, biosecurity within livestock, and increasing animal vaccine prescriptions accelerate the development of the China Porcine Vaccines Market. One of the most important drivers for the growth of this market encompasses the growth in government policies aimed at the improvement of pork production in China. The Chinese government has put into place a strong biosecurity regulation policy of disease control in pigs which has increased the demand for appropriate vaccination solutions. Moreover, Rufus's recent concern over the control of disease in pigs has made it necessary for these farmers to adopt these vaccines to ensure herd stability. Numerous opportunities are waiting to be explored within the market, especially with the implementation of new and effective vaccine technologies like recombinant vaccines and other sophisticated delivery systems. The pulse on the PRRS vaccine development and marketing focuses on more tailored strategies of disease management. Moreover, they are aligning with preventive measures, thus increasing opportunities for industry growth. Lately, there has been an upsurge in partnerships between local businesses and foreign biotech companies to strengthen local R&D facilities for vaccine production. Besides, there is increasing attention to educating farmers on the importance of vaccination which is creating a more enlightened market. The pivot towards more eco-friendly farming approaches is also impacting the market as stakeholders look for ways to increase efficiency without compromising on animal and land welfare. All these factors and trends indicate a constantly evolving China Porcine Vaccines Market that is set to tackle the challenges of the future. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Porcine Vaccines Market Drivers** **Rising Demand for Pork Products in China** The increasing consumption of pork in China drives the need for effective disease control in swine. The Chinese Ministry of Agriculture and Rural Affairs reported that pork accounts for approximately 60% of meat consumption in the country, with a consumption rate estimated at 54 million tons in 2020. This rising demand pushes pig farmers to seek vaccination solutions to protect their livestock against diseases, enhancing the growth of the China Porcine Vaccines Market Industry.Furthermore, as the population grows, meat consumption is expected to continue rising, necessitating more robust vaccine development and distribution efforts. **Government Initiatives and Support** The Chinese government has increasingly prioritized livestock health, implementing policies and funding initiatives to support the development and distribution of vaccines. As part of the National Pig Industry Development Plan announced in recent years, the government has earmarked substantial investments to strengthen animal health management. This involves promoting vaccination to prevent diseases such as African Swine Fever, which has had devastating effects on swine populations.The policy frameworks and support from the Ministry of Agriculture significantly influence the growth dynamics of the China Porcine Vaccines Market Industry. **Advancements in Vaccine Technology** Technological advancements in vaccine research and development have catalyzed the growth of the China Porcine Vaccines Market Industry. Innovative vaccine technologies, such as DNA vaccines and recombinant vaccines, offer improved efficacy and safety over traditional methods. The recognition of these advancements is seen in various patent filings aimed at enhancing swine health. According to Chinese Patent Office filings, there has been a marked increase in vaccine-related patents filed in the past five years, with over 500 new patents focusing on swine health solutions. This growth reflects the strong push for advanced vaccine solutions in the market. **China Porcine Vaccines Market Segment Insights** **Porcine Vaccines Market Type Insights** The China Porcine Vaccines Market, categorized by Type, encompasses several key segments, including Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, and DNA vaccines, each contributing uniquely to the market landscape. Inactivated vaccines have historically gained traction due to their proven efficacy and safety in providing immunity against various swine diseases. Meanwhile, Live attenuated vaccines often demonstrate a robust immune response, making them significant for protecting pigs from infectious agents. Toxoid vaccines hold importance in preventing diseases caused by toxins, reinforcing the immune response in swine populations. Recombinant vaccines represent an innovation in the market, offering increased precision in targeting specific pathogens, which is particularly vital in complex viral infections. Conjugate vaccines enhance the immune response by linking polysaccharides to proteins, thereby offering better protection against specific bacterial infections in pigs. DNA vaccines are emerging as a cutting-edge technology, showcasing the potential for quicker development times and adaptability against evolving pathogens. The Chinese government has shown increased commitment to animal husbandry regulations, which, alongside growing concerns about livestock health, serves as a pivotal driver for the adoption of various types of porcine vaccines.  Rising pig production, supported by a large domestic market, further stimulates demand across these segments of the China Porcine Vaccines Market. Moreover, enhancing biosecurity measures and technological advancements in vaccine development signify a trend toward prioritizing efficient and effective vaccination practices in the swine industry. Overall, the segmentation within the China Porcine Vaccines Market showcases a rich spectrum of options tailored to meet the evolving needs of animal health, emphasizing the vital role of vaccinations in ensuring sustainable swine production and disease control. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Porcine Vaccines Market Disease Indication Insights** The China Porcine Vaccines Market, particularly in the context of Disease Indication, reflects a significant portion of the country’s livestock health strategy. Disease prevention is crucial for the productivity of the pork industry, which plays a major economic role in China. Various diseases impact pig populations, notably the Porcine Epidemic Diarrhea (PED) and Porcine Reproductive and Respiratory Syndrome (PRRS), both of which have prompted increased vaccine development efforts. The dominance of these diseases underlines the urgency for effective vaccination programs to ensure herd immunity and reduce economic losses. Additionally, Swine Influenza and Aujeszky's Disease pose serious threats to animal health, reinforcing the need for vaccines tailored to these pathogens. Porcine Circovirus Associated Disease (PCVAD) has gained attention in the past years due to its impact on growth and health outcomes in pigs. The diverse range of diseases covered under this market segment indicates the necessity for comprehensive vaccination solutions, leading to ongoing Research and Development initiatives aimed at enhancing vaccine efficacy. Overall, the segmentation of the China Porcine Vaccines Market reveals significant trends towards specialization and innovation in vaccine development to address the distinct challenges presented by these diseases, highlighting their importance in safeguarding livestock and bolstering the sector's growth. **Porcine Vaccines Market End-user Insights** The End-user segment of the China Porcine Vaccines Market plays a crucial role in the overall health management and productivity of the swine industry. Veterinary Hospitals are fundamental in providing essential healthcare services, including vaccination, which helps prevent disease outbreaks among pig populations. These facilities often serve as the primary contact point for hog producers seeking expert advice and personalized healthcare strategies, thereby enhancing the overall health standards within farms. On the other hand, Hog Production Farms are significant as they represent the primary consumers of porcine vaccines, utilizing these products to safeguard animal health and ensure optimal growth and productivity. The growing awareness of biosecurity measures and the increasing incidences of porcine diseases further enhance the importance of vaccines in these settings. The trends indicate that as the swine industry in China continues to expand, the demand for efficient vaccination solutions tailored to these end-users is also expected to increase, thus driving the growth of the overall market. The importance of innovative vaccine solutions, along with improved access to veterinary services, presents significant opportunities within this segment, reflecting a positive outlook for the future of the China Porcine Vaccines Market. **China Porcine Vaccines Market Key Players and Competitive Insights** The China Porcine Vaccines Market is characterized by robust competition, influenced by a growing demand for swine health management and advancements in vaccine technology. As the pork industry is crucial to China's economy, ensuring the health of the swine population has become increasingly paramount. Key players in this market are continuously innovating to meet the stringent health regulations and to counteract threats posed by various swine diseases, such as African Swine Fever and Porcine Reproductive and Respiratory Syndrome. The competitive landscape is shaped by factors such as product efficacy, distribution channels, pricing strategies, and partnerships with local veterinary services and governmental bodies, thereby creating a dynamic environment for market participants. Focusing on CEVA Animal Health, the company has established a significant foothold in the China Porcine Vaccines Market through its innovative product offerings and commitment to swine health. CEVA's strengths lie in its extensive research and development capabilities that allow for the creation of vaccines targeted at specific swine diseases prevalent in the region. Their focus on quality assurance and adherence to local regulations has reinforced their reputation among veterinarians and swine producers. By fostering strong relationships with local stakeholders and delivering reliable vaccination programs, CEVA Animal Health has effectively positioned itself as a trusted player in the market, ensuring it meets the evolving needs of its customers in China. Merial, now part of a larger global entity, has also carved out a niche in the China Porcine Vaccines Market with its comprehensive range of vaccine products aimed at combating various infectious diseases affecting pigs. Noteworthy products from Merial focus on controlling Porcine Circovirus and Erysipelas, among others, which are critical to maintaining healthy livestock. Through a combination of innovative technologies and strategic partnerships, Merial has managed to expand its market presence in China significantly.  Their strengths are not only attributed to their robust product pipeline but also to various mergers and acquisitions that have enhanced their capabilities and market reach. By continuing to invest in localized strategies and engaging with local farmers and veterinarians, Merial retains a competitive edge that allows it to respond effectively to the specific challenges faced by swine producers in China. **Key Companies in the China Porcine Vaccines Market Include** **China Porcine Vaccines Market Industry Developments** Recent developments in the China Porcine Vaccines Market have been dynamic, particularly with a growing emphasis on the prevention of diseases like African Swine Fever (ASF). This has led companies like Zoetis and Boehringer Ingelheim to enhance their product portfolios, resulting in overall increased market growth. In 2022, the market valuation significantly rose, driven by rising awareness of animal health and intensifying production practices. Notably, in September 2023, CEVA Animal Health announced an expansion of their vaccine offerings in China, aiming to cater to the burgeoning demand for effective porcine vaccines.  In terms of mergers and acquisitions, in October 2023, Vetoquinol acquired a minority stake in Herd Health Biosecurity, signaling consolidation in the market to address health challenges better facing the porcine industry. This strategic move is expected to improve product development and distribution capabilities. Additionally, the China Animal Husbandry Industry Co has been actively integrating new technologies into vaccine research, which is further propelling the market forward in terms of innovation. The focus remains not only on existing diseases but also on increasing biosecurity measures across the livestock sector in China to ensure long-term sustainability and health management. **China Porcine Vaccines Market Segmentation Insights** ## Market Drivers ### Emerging Infectious Diseases The emergence of new infectious diseases poses a substantial threat to the swine industry in China, thereby influencing the porcine vaccines market. Recent outbreaks of diseases such as African Swine Fever (ASF) have highlighted the vulnerability of pig populations. The need for effective vaccines to combat these diseases is becoming increasingly urgent. In response, the Chinese government and private sector are investing in research and development to create vaccines that can effectively mitigate these threats. The potential for significant economic impact from disease outbreaks underscores the necessity for robust vaccination programs, which may drive growth in the porcine vaccines market as producers seek to protect their herds. ### Increasing Livestock Production The rising demand for pork in China is driving the porcine vaccines market. As the population grows, the need for efficient livestock production intensifies. In 2025, pork consumption in China is projected to reach approximately 60 million metric tons, necessitating enhanced health management practices. Vaccination plays a crucial role in maintaining herd health and productivity, thereby supporting the overall growth of the porcine vaccines market. Farmers are increasingly recognizing the importance of vaccination in preventing disease outbreaks, which can lead to significant economic losses. Consequently, the focus on improving livestock production efficiency is likely to propel the demand for innovative vaccines tailored to the specific needs of the Chinese market. ### Regulatory Framework Enhancements The regulatory environment surrounding animal health in China is evolving, which is influencing the porcine vaccines market. The government is implementing stricter regulations to ensure the safety and efficacy of vaccines. These enhancements are aimed at improving the overall health of livestock and reducing the incidence of disease outbreaks. As a result, vaccine manufacturers are encouraged to innovate and comply with these regulations, leading to the development of more effective products. The increased focus on regulatory compliance may create opportunities for growth in the porcine vaccines market, as producers seek to align with government standards and improve herd health. ### Rising Awareness of Animal Health There is a growing awareness among Chinese farmers regarding the importance of animal health, which is positively impacting the porcine vaccines market. Educational initiatives and outreach programs are helping farmers understand the benefits of vaccination in preventing diseases and ensuring the well-being of their livestock. This shift in mindset is likely to lead to increased adoption of vaccination protocols, thereby enhancing herd immunity and productivity. As farmers become more informed about the economic advantages of maintaining healthy pigs, the demand for effective vaccines is expected to rise. This trend indicates a promising future for the porcine vaccines market as awareness continues to expand. ### Technological Innovations in Vaccine Delivery Technological advancements in vaccine delivery systems are transforming the porcine vaccines market. Innovations such as needle-free vaccination methods and improved adjuvants are enhancing the efficacy and ease of vaccine administration. These developments are particularly relevant in China, where large-scale pig farming operations require efficient vaccination strategies. The introduction of more user-friendly delivery systems may encourage greater adoption of vaccines among farmers, ultimately leading to improved herd health and productivity. As these technologies continue to evolve, they are likely to play a pivotal role in shaping the future landscape of the porcine vaccines market. ## Future Outlook The [Porcine Vaccines Market](https://www.marketresearchfuture.com/reports/porcine-vaccines-market-7438) in China is projected to grow at a 5.14% CAGR from 2025 to 2035, driven by increasing demand for disease prevention and advancements in vaccine technology. **New opportunities:** - Development of customized vaccine formulations for specific regional diseases. - Expansion of digital platforms for vaccine tracking and management. - Investment in R&D for next-generation vaccines targeting emerging pathogens. By 2035, the porcine vaccines market is expected to achieve robust growth and enhanced market dynamics. ## Segment Insights ### By Type: Inactivated vaccines (Largest) vs. Live attenuated vaccines (Fastest-Growing) In the China porcine vaccines market, inactivated vaccines dominate the landscape, accounting for a significant portion of the market share due to their established effectiveness and safety profile. Live attenuated vaccines, while smaller in market share, are rapidly gaining traction due to their potency and ability to induce long-lasting immunity, making them an attractive option for swine producers looking for efficient solutions. The growth trends in this segment are driven by increasing demand for food safety and the rising prevalence of swine diseases, pushing producers towards effective vaccination strategies. Furthermore, government initiatives aimed at improving livestock health and productivity are fueling investments in vaccine R&D, leading to innovations in live attenuated and recombinant vaccine technologies that promise to enhance the efficacy of disease control in the swine population. Inactivated vaccines (Dominant) vs. Live attenuated vaccines (Emerging) Inactivated vaccines remain the dominant player in the China porcine vaccines market due to their long-standing reputation for effectiveness and comprehensive safety. They are typically used as a primary preemptive measure against various infectious diseases in swine, leveraging inactivated pathogens to stimulate immunity without causing disease. Conversely, live attenuated vaccines are emerging as a popular choice among producers looking for solutions that provide strong immunity with minimal doses. These vaccines use weakened forms of pathogens to elicit robust immune responses, making them particularly appealing for their efficiency and cost-effectiveness in large scale operations. This growing interest in live attenuated vaccines reflects a shift towards advanced, efficient vaccination methods in swine production. ### By Disease Indication: PRRS (Largest) vs. PED (Fastest-Growing) In the China porcine vaccines market, the disease indication segment is predominantly led by Porcine Reproductive & Respiratory Syndrome (PRRS), which holds the largest market share due to its widespread prevalence and significant impact on swine health. Porcine Epidemic Diarrhea (PED) follows as a notable contender, gaining traction rapidly in recent years. The market also includes other diseases such as Swine influenza, Aujeszky's disease, and Porcine Circovirus Associated Disease; however, they command smaller shares compared to PRRS and PED. The growth trends in the disease indication segment are largely driven by increasing awareness among farmers about the health implications of swine diseases and the economic benefits of vaccination. Furthermore, advancements in vaccine technologies and growing government initiatives to support the swine industry are anticipated to bolster the demand for PED vaccines, making it one of the fastest-growing segments in the market. Emerging strains and the need for effective disease management solutions also contribute significantly to the rising interest in this segment. PRRS (Dominant) vs. PED (Emerging) PRRS is recognized as the dominant disease indication in the China porcine vaccines market, characterized by its extensive impact on reproductive and respiratory health in swine. This condition results in significant economic losses for farmers, which underlines the critical role of vaccination. Conversely, PED, while still emerging, has garnered increased attention due to its rapid onset and high mortality rates in young pigs. The swift adaptation of vaccine formulations to combat PED highlights its rising importance in the market. Both segments are characterized by ongoing research and development for more effective vaccines, driven by the need for sustainable livestock management practices in the face of evolving disease threats. ### By End-user: Veterinary Hospitals (Largest) vs. Hog Production Farm (Fastest-Growing) In the China porcine vaccines market, the market share is significantly skewed towards veterinary hospitals, which cater to a wide range of animal health needs and have established networks for vaccine distribution. This segment dominates due to the solid infrastructure and consistency in service provision, thus attracting a larger clientele. In contrast, hog production farms, while currently smaller in terms of share, are rapidly expanding, reflecting the agricultural push for larger-scale operations and enhanced biosecurity measures in livestock health management. The growth trends are particularly favorable for hog production farms, driven by increasing investment in livestock and the rising demand for pork in China. Farmers are becoming more aware of vaccination's vital role in maintaining herd health and productivity, leading to increased adoption rates. Additionally, government initiatives aiming at boosting agricultural productivity and biosecurity practices contribute to the expansion of this segment, positioning it as the fastest-growing in the market. Veterinary Hospitals (Dominant) vs. Hog Production Farm (Emerging) Veterinary hospitals in the China porcine vaccines market are characterized by their established presence, comprehensive service offerings, and pivotal role in animal healthcare. They leverage advanced technologies and skilled professionals to deliver efficient vaccination programs, thus ensuring livestock are protected from prevalent diseases. This domination is complemented by strong relationships with food supply chains and a loyal customer base. On the other hand, hog production farms are emerging due to the growing emphasis on biosecurity and herd management. These farms are increasingly adopting vaccines to mitigate disease risks and enhance production efficiency. As the local pig farming industry becomes more industrialized, the importance of these farms in the overall vaccine market landscape is set to rise, attracting new investments and fostering innovation. ## Competitive Benchmarking The porcine vaccines market in China is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are at the forefront, leveraging their extensive research capabilities and established market presence to drive growth. These companies appear to focus on developing advanced vaccine formulations and enhancing their distribution networks, which collectively fosters a dynamic competitive environment. The emphasis on innovation and strategic collaborations among these firms suggests a trend towards more sophisticated vaccine solutions tailored to the specific needs of the Chinese market.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with the growing emphasis on sustainability. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their ability to optimize supply chains and localize production is likely to set them apart in a competitive landscape that demands agility and responsiveness. In October Zoetis (US) announced the launch of a new vaccine specifically targeting Porcine Reproductive and Respiratory Syndrome (PRRS), a significant disease affecting swine health. This strategic move underscores Zoetis's commitment to addressing critical health challenges in the porcine sector, potentially enhancing its market share in China. The introduction of this vaccine is expected to bolster the company's portfolio and reinforce its position as a leader in swine health solutions.Similarly, in September 2025, Merck Animal Health (US) expanded its partnership with local Chinese veterinary institutions to enhance research and development capabilities. This collaboration aims to accelerate the development of vaccines tailored to regional disease challenges. By investing in local partnerships, Merck is likely to strengthen its foothold in the Chinese market, ensuring that its products are well-suited to the specific needs of local farmers and veterinarians. In August Boehringer Ingelheim (DE) launched a digital platform aimed at improving vaccine management and tracking for swine producers. This initiative reflects a broader trend towards digitalization in the agricultural sector, where technology is increasingly integrated into traditional practices. By providing farmers with tools to monitor vaccine efficacy and animal health, Boehringer Ingelheim is positioning itself as a forward-thinking leader in the market, likely enhancing customer loyalty and operational efficiency. As of November the competitive trends in the porcine vaccines market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and reliable supply chains. This shift may ultimately lead to a more resilient and responsive market, better equipped to meet the challenges of the future. ## Recent News & Developments Recent developments in the China Porcine Vaccines Market have been dynamic, particularly with a growing emphasis on the prevention of diseases like African Swine Fever (ASF). This has led companies like Zoetis and Boehringer Ingelheim to enhance their product portfolios, resulting in overall increased market growth. In 2022, the market valuation significantly rose, driven by rising awareness of animal health and intensifying production practices. Notably, in September 2023, CEVA Animal Health announced an expansion of their vaccine offerings in China, aiming to cater to the burgeoning demand for effective porcine vaccines.  In terms of mergers and acquisitions, in October 2023, Vetoquinol acquired a minority stake in Herd Health Biosecurity, signaling consolidation in the market to address health challenges better facing the porcine industry. This strategic move is expected to improve product development and distribution capabilities. Additionally, the China Animal Husbandry Industry Co has been actively integrating new technologies into vaccine research, which is further propelling the market forward in terms of innovation. The focus remains not only on existing diseases but also on increasing biosecurity measures across the livestock sector in China to ensure long-term sustainability and health management. ## Report Scope | MARKET SIZE 2024 | 144.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 151.4(USD Million) | | MARKET SIZE 2035 | 250.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.14% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR) | | Segments Covered | Type, Disease Indication, End-user | | Key Market Opportunities | Advancements in vaccine technology enhance disease control in the porcine vaccines market. | | Key Market Dynamics | Rising demand for innovative porcine vaccines driven by regulatory changes and heightened biosecurity concerns in livestock management. | | Countries Covered | China | ## Frequently Asked Questions **Q: What was the market valuation of the China porcine vaccines market in 2024?** A: The market valuation was $144.0 Million in 2024. **Q: What is the projected market valuation for the China porcine vaccines market by 2035?** A: The projected valuation for 2035 is $250.0 Million. **Q: What is the expected CAGR for the China porcine vaccines market during the forecast period 2025 - 2035?** A: The expected CAGR is 5.14% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the China porcine vaccines market?** A: Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, Ceva Santé Animale, Virbac, Heska Corporation, and Vetoquinol. **Q: What are the main types of vaccines in the China porcine vaccines market?** A: Main types include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. **Q: What was the market size for live attenuated vaccines in 2024?** A: The market size for live attenuated vaccines was between $50.0 Million and $90.0 Million in 2024. **Q: What is the market size for PRRS vaccines in 2024?** A: The market size for PRRS vaccines ranged from $40.0 Million to $70.0 Million in 2024. **Q: What segment had the highest market size in the end-user category in 2024?** A: The hog production farm segment had the highest market size, ranging from $104.0 Million to $180.0 Million in 2024. **Q: What is the projected growth trend for the inactivated vaccines segment from 2024 to 2035?** A: The inactivated vaccines segment is expected to grow from $40.0 Million to $70.0 Million by 2035. **Q: How does the market size for Porcine Circovirus Associated Disease (PCVAD) vaccines compare to other disease indications in 2024?** A: The market size for PCVAD vaccines ranged from $20.0 Million to $35.0 Million, indicating a moderate position among disease indications. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-porcine-vaccines-market-50482*